International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2019
Multicenter Study Clinical TrialA Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
The purpose of this study is to assess the utility of 68Gallium prostate-specific membrane antigen (PSMA) Division of Radiopharmaceutical Chemistry (DKFZ)-PSMA-11 positron emission tomography (PET)-computed tomography (CT), compared with standard imaging, in the detection of recurrent prostate carcinoma in patients with biochemical relapse to determine the prevalence of oligometastatic disease recurrence and its distribution. ⋯ For patients with biochemical relapse with BS and CT demonstrating either no disease or low-volume disease, there is a high overall prevalence of PSMA PET/CT-positive disease. More than half of the patients were oligometastatic, and of those, disease was confined to the pelvis in nearly two-thirds of patients. This result confirms that PSMA PET/CT is significantly more sensitive than standard restaging imaging, and it may be useful in identifying patients for subsequent targeted therapy.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2019
Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy.
This study explores the efficacy and safety of reirradiation with modern radiation therapy techniques in patients previously irradiated for prostate cancer and affected by local relapse of disease. ⋯ Reirradiation of patients with prostate cancer who underwent previous radiation therapy is a valuable option that can be safely considered to delay the beginning of hormonal treatment.